MXC-017
MXC-017 is a blood-brain barrier (BBB)-penetrant apoptosis inducer that directly targets Vimentin (VIM). MXC-017 prevents radiation-induced glioma stem cell (GSC) formation, while promoting G0/G1 cell cycle arrest and apoptosis. MXC-017 exhibits minimal off-target effects and shows no significant cytotoxicity. MXC-017 significantly prolongs median survival when used in combination with radiation therapy in glioblastoma (GBM) mouse models.
For research use only. We do not sell to patients.
- CAS No.: 3037024-97-5
- Formula: C21H23N3O3S
- Molecular Weight:397.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
MXC-017 (1-10 μM, 5-7 days) displays no radiosensitizing effect, but prevents radiation-induced induction of marker-positive cells, and dose-dependently reduces sphere formation in HK-374, HK-345 and HK-157 cells with acceleration of GSC exhaustion in HK-374 and HK-217 cells at 10 μM[1].
MXC-017 (1-10 μM, 10 days) significantly reduces GSC frequencies alone or combination with radiation in HK-374, HK-390, HK-217, HK-146, HK-308 and HK-345 cells[1].
MXC-017 (10 µM, 2-5 days) increases the radiation-induced G0/G1 arrest with reduction number of cells in S phase, and significantly increases the proportion of apoptotic cells after 4 Gy irradiation in HK-374 cells[1].
MXC-017 (10 µM, 0.25-24 h) binds to vimentin and prevents decompaction of vimentin intermediate filaments, with no protein levels change in total vimentin and phosphorylation of Ser39, Ser56, or Ser83 in HK-374 cells[1].
MXC-017 (10 µM, 6-24 h) reduces detectable baseline levels of vimentin and preventes the radiation induced increase of the vimentin signal, while no change in total vimentin levels in HK-374 cells [1].
MXC-017 (10 µM, 16-24 h) significantly suppresses the migratory capacity of HK-374 cell with combination of radiation in an independent manner[1].
MXC-017 (10 µM, 48 h) has no off-target effects with no metabolic modulation changes, but induces 357 differentially expressed genes (239 up, 118 down), enriching KRAS activation (pro-inflammatory response) and suppressing E2F/G2M checkpoint, without cellular composition changes in HK-374, HK-390, HK-217 and HK-244 cells[1].
MXC-017 (1-10 µM, 24 h) causes no significant toxicity in NSP cells (up to 2.5 µM), NIH3T3 and EOC20 cells (up to 10 µM), but significant decreases plating efficacy in normal human astrocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HK-374 cells
-
Concentration:10 μM, with or without a single dose of 4 Gy irradiation
-
Incubation Time:16-24 h
-
Result:Significantly reduced the migratory capacity of GBM cells with little cells penetrating through the membrane.
Displayed Markedly impaired migration compared to untreated or radiation-only controls.
-
Cell Line:HK-374 cells
-
Concentration:10 μM, with or without a single dose of 4 Gy irradiation
-
Incubation Time:2 or 5 days
-
Result:Enhanced the radiation-induced G0/G1 arrest and reduced the number of cells in S phase after 4 Gy irradiation.
-
Cell Line:HK-374 cells
-
Concentration:10 μM, with or without a single dose of 4 Gy irradiation
-
Incubation Time:72 h
-
Result:Did not induce apoptosis with 4 Gy irradiation or treatment alone.
Significantly reduced the viable cell population and increased the proportion of apoptotic cells in combination with 4 Gy irradiation.
-
Cell Line:HK-374 cells
-
Concentration:10 μM
-
Incubation Time:0.25, 0.5, 1, 2, 4, 6, 24 h
-
Result:Did not change the protein levels of total vimentin or phosphorylation of Ser39, Ser56, or Ser83 by using a polyclonal antibody.
In Vivo
MXC-017 (150-900 mg/kg, i.p., once or 5 consecutive days per week for 2 weeks) cause a maximum tolerated dose of 150 mg/kg without clinical signs of toxicity and significant hematological or biochemical abnormalities in C57BL/6 mice model[1].
MXC-017 (150 mg/kg, i.p., 5-days on/2-days off for >140 days) significantly reduces the probability for tumor related death in PDOX GBM mice model with combination of radiation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female and male NSG mice (6-8 weeks old) were implanted into the right striatum of the brains with HK-374 cells (2 × 105 cells/mouse)[1].
-
Dosage:50 mg/kg or irradiation (4 or 10 Gy)
-
Administration:i.p., 5-days on/2-days off for 2 weeks after implanting HK-374 cells 3 days, and then collected brain and tumors samples.
-
Result:Reduced the number of spheres formation and significantly decreased the GSC frequency by MXC-017 treatment alone and in combination with 4 Gy radiation.
Significantly increased the median survival from 34 to 60 days in PDOX GBM mice model with combination of 10 Gy radiation.
Effectively eliminated implanted HK-374 cells in combination with 10 Gy radiation.
Caused tumor-free in long-term surviving PDOX GBM mice at the time of euthanasia in combination with 10 Gy radiation.
Did not change the proportions of the cell types in PDOX GBM mice model.
Effectively eliminated nestin-positive human tumor cells without loss of olig2-positive oligodendrocytes in the contralateral (non-tumor-bearing) hemisphere in combination with 10 Gy radiation.
-
Animal Model:Female and male C57BL/6 mice (6-8 weeks old)[1].
-
Dosage:Once administration (150, 300, 600, and 900 mg/kg), repeated administration (150, 300, 600 mg/kg)
-
Administration:i.p., once in pairs (1 male/1 female) or 5 consecutive days per week in groups (3 male/ 3 female) for 2 weeks.
-
Result:Caused no signs of toxicity with once administration up to 900 mg/kg.
Caused no clinical signs of toxicity and no significant hematological or biochemical abnormalities with repeated administration up to 600 mg/kg.
Caused mild toxicity with perivascular inflammation and superficial vasculitis at 150 mg/kg and acute pneumonia at 600 mg/kg in the lungs with repeated administration.
Caused focal interstitial inflammation in the kidney cortex at 300 mg/kg with repeated administration.
Caused focal lobular inflammation and hepatocellular necrosis in liver at 600 mg/kg with repeated administration.
-
Animal Model:Female and male NSG mice (6-8 weeks old) were implanted into the right striatum of the brains with 17 different PDOXs cells [1].
-
Dosage:150 mg/kg, 66 mg/kg (Temozolomide), irradiation
-
Administration:i.p., (Temozolomide: p.o.), 5-days on / 2-days off for >140 days.
-
Result:Significantly reduced the probability for tumor related death compared in PDOX GBM mice model with combination of radiation, outperforming Temozolomide.
Chemical Information
-
CAS No. 3037024-97-5
-
Molecular Weight 397.49
-
Formula C21H23N3O3S
-
SMILES
O=C(NCC1=CC=C(S(=O)(N2CCCCC2)=O)C=C1)N3C4=CC=CC=C4C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)